Lean Mass Loss on GLP-1s: What the DXA Substudies Show, and the Protein and Resistance-Training Evidence for Protecting Muscle

The concern, stated fairly

Any large weight loss removes lean tissue as well as fat. The concern raised about GLP-1s is that their weight loss is large and fast enough, and their appetite suppression severe enough, that the lean-mass fraction might be higher than with other methods, and that patients — especially older ones — might lose strength, function and resting metabolism they cannot get back. It is a legitimate concern, and the data address it better than the headlines suggest.

What the trials measured

SURMOUNT-1 DXA substudy (160 participants): at 72 weeks, total body mass fell about 21%; fat mass fell about 33% and lean mass about 11%. Lean mass accounted for roughly 25% of total weight lost. The proportion of the body that was lean rose, because fat fell faster.

STEP 1 DXA substudy (140 participants): at 68 weeks, total mass fell about 15%; fat mass about 20% and lean mass about 10%. Lean mass accounted for roughly 39% of weight lost.

Are those numbers alarming? The reference point is diet-induced weight loss, where lean mass typically makes up 20-35% of weight lost, more with rapid or very-low-calorie diets. Bariatric surgery runs 20-30%. The GLP-1 figures sit inside that range, tirzepatide toward the low end and semaglutide toward the high end, though the two substudies are not directly comparable.

What "lean mass" is

Lean mass on DXA is everything that is not fat or bone: skeletal muscle, water, organs, connective tissue. Weight loss reduces the water and organ components — a smaller body needs less blood volume and less liver — and that is not a loss of function. Skeletal muscle is the part that matters for strength, and DXA cannot separate it cleanly. The functional data are more reassuring than the mass data: in the STEP substudies, physical function scores improved, and in a tirzepatide analysis, strength and mobility improved. Losing 10% of lean mass while losing 33% of fat mass leaves a lighter body with a higher lean fraction, which is generally stronger relative to its weight.

The cases where muscle loss becomes clinically important are older adults, patients with low muscle mass to begin with (sarcopenic obesity), and patients who lose weight very rapidly with minimal protein intake and no exercise. For them, lean-mass loss can mean falls, frailty and a lower resting metabolism that makes regain more likely.

Why it matters for the long term

Two reasons. Resting energy expenditure depends substantially on lean mass; losing muscle lowers the calories burned at rest and steepens the regain curve if treatment stops (see SURMOUNT-4). And regain after weight loss is disproportionately fat: a patient who loses 20 kg (5 kg lean) and regains 15 kg may regain 14 kg of fat, ending with less muscle and nearly as much fat as at the start. Preserving muscle during loss protects against both.

Protein

The intervention with the most evidence during a large energy deficit is adequate protein. Trials of high-protein versus normal-protein diets during weight loss consistently show better preservation of lean mass at intakes of about 1.2 to 1.6 g per kilogram of body weight per day, with some data supporting up to 2.0 g/kg in resistance-trained individuals. Distribution matters: muscle protein synthesis is stimulated by 25-40 g of protein per meal, so three or four protein-containing meals outperform one large one.

On a GLP-1 this is hard. Appetite suppression cuts total intake, meals are small, and protein-rich foods (meat, eggs) are often the ones that trigger nausea in the first weeks. Practical approaches: protein first at each meal; dairy, eggs, fish, legumes and protein supplements (whey, casein) for patients who cannot face meat; a protein target in grams rather than a vague instruction. The protein and water tool computes a daily target and per-meal split. The calorie calculator shows the intake floor below which muscle loss accelerates.

Resistance training

The trials that established resistance training's role were in diet-induced loss: Villareal's 2017 trial in older adults with obesity found that adding resistance training to a diet preserved lean mass and improved function far better than diet alone or diet plus aerobic exercise. GLP-1-specific trials are under way; a 2024 review by Neeland and colleagues concluded that the mechanisms are the same and that resistance training two to three times weekly is the reasonable recommendation. Early GLP-1 exercise data from the semaglutide programs support it.

The prescription is unglamorous: two to three sessions a week of progressive resistance exercise covering major muscle groups — squats or leg press, hinges, pushes, pulls — with loads increased over time. Bodyweight and band exercises work for beginners. Aerobic exercise is valuable for cardiovascular fitness but does not preserve muscle the way loading does. Patients who have never trained should start light and, if possible, with instruction.

The pharmaceutical response

The industry considers lean-mass loss enough of a problem to be developing drugs for it: bimagrumab (an activin receptor blocker) combined with semaglutide, and enobosarm with GLP-1s, are in trials aimed at preserving or increasing muscle during weight loss. Early results show substantially lower lean-mass loss. None is approved, and none replaces protein and training, which are free.

What to do

Set a protein target in grams and hit it, even when appetite is gone. Train with resistance two or three times a week. Weigh, but also track strength and function — a grip-strength meter or simply the weight you can lift. Ask your clinician about a DXA scan at baseline and after a year if you are older or start with low muscle. And plan for maintenance (our guide), because the muscle preserved during loss is the muscle that keeps regain at bay.

Sources

1. Look M et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab 2025
2. Wilding JPH et al. STEP 1 body composition substudy (DXA). N Engl J Med 2021;384:989-1002, supplementary appendix
3. Conte C et al. Is weight loss-induced muscle mass loss clinically relevant? JAMA 2024;332:9-10
4. Villareal DT et al. Aerobic or resistance exercise, or both, in dieting obese older adults. N Engl J Med 2017;376:1943-1955
5. Phillips SM. Dietary protein requirements and adaptive advantages in athletes. Br J Nutr 2012;108 Suppl 2:S158-167
6. Neeland IJ et al. Changes in lean body mass with GLP-1-based therapies and mitigation strategies. Diabetes Obes Metab 2024;26:16-27

Citations are to primary sources (peer-reviewed trials, FDA labeling and announcements, and provider pricing pages). See our sources policy and corrections log.